Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 food-effect study of TAS-205 in healthy volunteers
jRCT2071230028Phase 1Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pizuglanstat in Duchenne muscular dystrophy (DMD) (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Cmax, AUClast and 1 more. Started Jul 2023; status: completed.
02
Drugs
pizuglanstat
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on jRCT2071230028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230028.